ATE360000T1 - Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung - Google Patents

Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Info

Publication number
ATE360000T1
ATE360000T1 AT02767010T AT02767010T ATE360000T1 AT E360000 T1 ATE360000 T1 AT E360000T1 AT 02767010 T AT02767010 T AT 02767010T AT 02767010 T AT02767010 T AT 02767010T AT E360000 T1 ATE360000 T1 AT E360000T1
Authority
AT
Austria
Prior art keywords
dihydroxy
vitamin
alpha
sub
oxime
Prior art date
Application number
AT02767010T
Other languages
German (de)
English (en)
Inventor
Gary H Posner
Jay A White
Glenville Jones
Bethany Halford
Mehmet Kahraman
Heung Bae Jeon
Original Assignee
Univ Johns Hopkins
Cytochroma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Cytochroma Inc filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE360000T1 publication Critical patent/ATE360000T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02767010T 2001-10-12 2002-10-11 Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung ATE360000T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32842801P 2001-10-12 2001-10-12

Publications (1)

Publication Number Publication Date
ATE360000T1 true ATE360000T1 (de) 2007-05-15

Family

ID=23280940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767010T ATE360000T1 (de) 2001-10-12 2002-10-11 Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Country Status (11)

Country Link
US (1) US6982258B2 (https=)
EP (1) EP1436257B1 (https=)
JP (1) JP4436674B2 (https=)
AT (1) ATE360000T1 (https=)
CA (1) CA2463505C (https=)
CY (1) CY1106638T1 (https=)
DE (1) DE60219655T2 (https=)
DK (1) DK1436257T3 (https=)
ES (1) ES2283593T3 (https=)
PT (1) PT1436257E (https=)
WO (1) WO2003031400A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
EP1301479A2 (en) 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
US20050059641A1 (en) * 2003-06-17 2005-03-17 Aphios Corporation Compositions and methods for treating and preventing cancer using analogs of vitamin D
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
US20070142339A1 (en) * 2004-05-10 2007-06-21 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006074227A2 (en) * 2005-01-04 2006-07-13 Johns Hopkins University HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS
WO2006113990A2 (en) * 2005-04-25 2006-11-02 Cytochroma Inc. LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3
WO2007047327A2 (en) * 2005-10-12 2007-04-26 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
SI3095447T1 (sl) * 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
US9481646B2 (en) * 2007-04-18 2016-11-01 The Johns Hopkins University Low calcemic, highly antiproliferative, analogs of calcitriol
US8592401B2 (en) * 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
PL2148661T3 (pl) 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
PT3335712T (pt) 2007-04-25 2025-10-23 Opko Renal Llc Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
DK2148684T3 (da) * 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
CN102046812A (zh) * 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US20100227414A1 (en) * 2009-03-05 2010-09-09 Trex Enterprises Corp. Affinity capture mass spectroscopy with a porous silicon biosensor
US9775903B2 (en) 2010-01-13 2017-10-03 Johns Hopkins University 1-deoxy analogs of 1,25-dihydroxyvitamin D3 compounds
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104557647B (zh) * 2015-01-13 2016-07-06 南京理工大学 维生素d肟类衍生物、合成方法及其应用
CN104945296B (zh) * 2015-06-09 2016-08-24 南京理工大学 一类芳香醛腙修饰的维生素d2衍生物、合成及其应用
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
CN117003679A (zh) * 2022-04-29 2023-11-07 南澳大利亚大学 新型抑制剂化合物
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
GB9623569D0 (en) * 1996-11-13 1997-01-08 Immunodiagnostic Systems Ltd Vitamin D immumoassay systems

Also Published As

Publication number Publication date
US20030171342A1 (en) 2003-09-11
CA2463505A1 (en) 2003-04-17
US6982258B2 (en) 2006-01-03
CY1106638T1 (el) 2012-01-25
CA2463505C (en) 2011-07-12
WO2003031400A1 (en) 2003-04-17
PT1436257E (pt) 2007-05-31
DK1436257T3 (da) 2007-06-25
EP1436257B1 (en) 2007-04-18
JP2005536444A (ja) 2005-12-02
DE60219655D1 (de) 2007-05-31
DE60219655T2 (de) 2007-12-27
ES2283593T3 (es) 2007-11-01
EP1436257A1 (en) 2004-07-14
JP4436674B2 (ja) 2010-03-24

Similar Documents

Publication Publication Date Title
ATE360000T1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
AR026173A1 (es) Inhibidores de neuraminidasas.
ES2139943T3 (es) Nuevos inhibidores de la sintasa de prostaglandina.
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
NO20031687L (no) Veksthormonsekretagoger
DK1474406T3 (da) Disubstituerede thiazolylcarboxanilider samt deres anvendelse som mikrobicider
BRPI0410081A (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
DK0863891T3 (da) (Methylsulfonyl)phenyl-2-(5H)-furanoner som COX2-inhibitorer
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
BRPI0410117A (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
SE0101675D0 (sv) Novel composition
NO331013B1 (no) Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
ATE543796T1 (de) 24-sulfoximine vitamin d3 derivate
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
DE60329326D1 (de) Tace inhibitoren
WO2004054968A3 (en) 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
ATE232847T1 (de) Alpha, beta-ungesättigte ketone
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1436257

Country of ref document: EP